Cabozantinib and Nivolumab Among Older Patients With Renal Cell Carcinoma

The goal of the study is to describe real-life use and exposition to nivolumab-cabozantinib among older patients with metastatic clear-cell renal cell cancer

Trial Details

NCT ID
NCT06934057
Phase
PHASE4
Sponsor
Gustave Roussy, Cancer Campus, Grand Paris
Status
RECRUITING
Cancer Type
Kidney Cancer
Interventions
  • Nivolumab
  • Cabozantinib
Locations (sample)
  • Angers, France|47.47156,-0.55202
  • Dijon, France|47.31344,5.01391
  • Lyon, France|45.74906,4.84789
  • Paris, France|48.85341,2.3488
  • Toulouse, France|43.60426,1.44367

Key Eligibility Criteria

  • Patients ≥ 70 years-old
  • Confirmed advanced or metastatic renal-cell carcinoma
  • Patients not previously treated in metastatic setting
  • Performance Status 0 to 2

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Kidney Cancer Trials on Trialify →